Search Results
Aug 06, 2026, 04:00 ET Clarivate Scales Agentic AI Across Cortellis to Advance Drug Development
Cortellis Drug Discovery Intelligence enable researchers to engage with complex drug intelligence through natural language, rapidly evaluate therapeutic landscapes, compare compounds and targets and
More news about: Clarivate Plc
Aug 06, 2026, 04:00 ET Clarivate Scales Agentic AI Across Cortellis to Advance Drug Development
Cortellis Drug Discovery Intelligence enable researchers to engage with complex drug intelligence through natural language, rapidly evaluate therapeutic landscapes, compare compounds and targets and
More news about: Clarivate Plc
Aug 06, 2026, 02:16 ET Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
medicines.Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, said: "Drug discovery increasingly depends on the ability to integrate deep disease biology with advanced experimental and computational approaches to drug discovery. This collaboration with Odyssey illustrates well Evotec's strategy
More news about: Evotec SE
Aug 06, 2026, 00:51 ET Fosun International Wins Three Awards from Global Banking & Finance Review, Gaining International Recognition for its ESG Performance, Corporate Social Responsibility, and Brand Strength
(NSCLC), gynecological tumors, and other indications. HLX22 is the world's first anti-HER2-targeted therapy to receive Orphan Drug Designation (ODD) approvals from both the US Food and Drug Administration (FDA) and the European Commission (EC) for gastric cancer.At the same time, Fosun Pharma is committed
More news about: Fosun
Aug 05, 2026, 21:05 ET Galibra Neuroscience Receives FDA Orphan Drug and Rare Pediatric Disease Designations for SSADH Deficiency Gene Therapy
/PRNewswire/ -- Galibra Neuroscience announced a significant regulatory milestone with the receipt of both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the U.S. Food and Drug Administration (FDA) for the company's investigational gene therapy for succinic semialdehyde dehydrogenase
More news about: Galibra Neuroscience
Aug 05, 2026, 20:30 ET AI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and Aging
HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the nomination of ISM9077, the AI-empowered, potential first-in-class Target Y inhibitor with pipeline-in-a-drug potential, as a Preclinical Candidate (PCC) for the treatment of ocular
More news about: Insilico Medicine
Aug 05, 2026, 20:00 ET Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China
long-term follow-up data from the above study, IBI363 in combination with bevacizumab was granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) in May 2026. The proposed indication is for patients with advanced microsatellite
More news about: Innovent Biologics
Aug 05, 2026, 16:21 ET Humla announces its digital nurse staffing marketplace is now a qualified solution on leading healthcare platform
license re-verification against source-of-truth databases and certifications every 24 hours, specialty and regulatory assessments, background checks, and drug screening — while giving facilities full visibility into every nurse's profile. Based on Humla client data, facilities using the solution have reduced
More news about: Humla Health
Aug 05, 2026, 16:05 ET Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026
exemption (IDE) as an anticoagulant for the extracorporeal circuit. Nafamostat has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).This release is intended for investors only. For additional information about Talphera, please visit
More news about: Talphera, Inc.
Aug 05, 2026, 16:05 ET Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
treatment duration of 35 weeks, as of the March 10, 2026 cutoff.Key outcomes from the End-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA):80 mg QD selected as the recommended dose for Phase 3 ENABLE-2 trial.ENABLE-2 is expected to enroll
More news about: Enliven Therapeutics, Inc.
Aug 05, 2026, 16:05 ET Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving,
More news about: Caris Life Sciences
Aug 05, 2026, 16:02 ET GRAIL Reports Second Quarter 2026 Financial Results
markets, including Japan and Singapore, subject to regulatory approvals and other conditions. GRAIL anticipates the U.S. Food and Drug Administration (FDA) will hold an advisory committee in the fall to review the Premarket Approval (PMA) application for the Galleri multi-cancer early
More news about: GRAIL, Inc.
Aug 05, 2026, 16:01 ET Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
Labour and Welfare (MHLW) granted orphan drug designation to Quimilza™ for the treatment of GPP. In July 2026, Vanda announced that the Committee for Orphan Medicinal Products at the European Medicines Agency (EMA) had adopted a positive opinion recommending orphan drug designation for Quimilza™ for the treatment
More news about: Vanda Pharmaceuticals Inc.
Aug 05, 2026, 16:01 ET Curaleaf Reports Second Quarter 2026 Results: Continued Growth, Margin Strength, and Profitability
TSX; potential legal, regulatory or political changes; licensing and ownership limitations; regulatory actions and approvals from the U.S. Food and Drug Administration ("FDA"), including the risk of increased FDA oversight; potential heightened scrutiny by regulators; loss of foreign private issuer status;
More news about: Curaleaf Holdings, Inc.
Aug 05, 2026, 14:45 ET Phoenix Nest Awarded Prestigious Small Business Innovation Research (SBIR) Grant of $2,984,658
supporting our manufacturing moves us another step closer to our goal of delivering therapy to the patients." Phoenix Nest has obtained an orphan drug designation and rare pediatric disease designation from the FDA for the JLK-247 gene therapy. Phoenix Nest has developed a video recording application
More news about: Phoenix Nest Inc.
Aug 05, 2026, 14:40 ET Olio Labs releases study showcasing AI-driven in vivo platform can predict clinical trial outcomes
has become easier, cheaper, and faster to make new molecules, there is a surge of drug candidates entering the preclinical stage. At the same time, clinical trial cost efficiency and optimization can't keep up, and drug developers need better tools to prioritize and decide which candidates should enter
More news about: Olio Labs
Aug 05, 2026, 12:15 ET GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Rapid Lab Validation
FRANCISCO, Aug. 5, 2026 /PRNewswire/ -- Artificial intelligence can now generate thousands of potential drug molecules in the time it once took to design one, dramatically expanding what scientists can imagine. Yet deciding which designs merit further investment
More news about: GenScript Biotech Corporation
Aug 05, 2026, 12:15 ET GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Rapid Lab Validation
FRANCISCO, Aug. 5, 2026 /PRNewswire/ -- Artificial intelligence can now generate thousands of potential drug molecules in the time it once took to design one, dramatically expanding what scientists can imagine. Yet deciding which designs merit further investment
More news about: GenScript Biotech Corporation
Aug 05, 2026, 11:01 ET Cold Spring Harbor Laboratory and Northwell Health lead international cohort of researchers to develop more than 150 next-generation cancer treatment models
David Spector, who assisted in the development of primary breast cancer and metastatic breast cancer organoids, said they allow for faster drug screens. "The ultimate goal is to use organoids as a means of testing drugs to determine the best combination for a particular tumor and
More news about: Cold Spring Harbor Laboratory
Aug 05, 2026, 10:45 ET Epilepsia Open publishes results of post hoc data analysis of FINTEPLA® (fenfluramine) in patients with Lennox-Gastaut syndrome
FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) in patients two years of age and older.¹Post hoc analysis of patients with LGS, transitioning from the
More news about: UCB
Aug 05, 2026, 10:31 ET Hyperphosphatemia Market Set for Robust Growth During the Forecast Period (2026-2036), Driven by Novel Therapeutics and Rising CKD Burden | DelveInsight
by Chugai Pharmaceutical Co., Ltd. before being licensed to Alebund Pharmaceuticals. The therapy is currently supported by active Investigational New Drug (IND) applications in both the United States and China, facilitating its ongoing clinical development.The anticipated launch of these emerging
More news about: DelveInsight Business Research, LLP
Aug 05, 2026, 10:07 ET Levi & Korsinsky Reminds Wise Group plc Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 29, 2026 - WSE
half a billion euros (approximately $582.5 million) in suspicious transactions, with alleged links to fraud, corruption and drug trafficking. The prosecutor's office indicated the inquiry began the prior year, was nearing completion, and that prosecutors were finalizing a direct
More news about: Levi & Korsinsky, LLP
Aug 05, 2026, 10:00 ET Blacksmith Medicines Announces Publication in Journal of Medicinal Chemistry Highlighting Discovery of a Non-Hydroxamate LpxC Inhibitor
solution by leveraging a proprietary metal-binding pharmacophore library to identify novel non-hydroxamate starting points for elaboration through rational drug design."Blacksmith's lead antibacterial candidate targeting LpxC, FG-2101, is being advanced for both intravenous and oral administration for
More news about: Blacksmith Medicines
Aug 05, 2026, 10:00 ET Altruist Biologics Completes First Commercial PPQ Campaign of its 20,000L Production Line at the Hangzhou Site
technical scale-up success, the company achieved substantial cost-of-good reduction with manufacturing costs reduced to below $50/g of monoclonal antibody drug substance. These improvements were enabled through economies of scale, implementation of advanced automation strategies, adoption of locally sourced
More news about: Altruist Biologics
Aug 05, 2026, 10:00 ET Altruist Biologics Completes First Commercial PPQ Campaign of its 20,000L Production Line at the Hangzhou Site
technical scale-up success, the company achieved substantial cost-of-good reduction with manufacturing costs reduced to below $50/g of monoclonal antibody drug substance. These improvements were enabled through economies of scale, implementation of advanced automation strategies, adoption of locally sourced
More news about: Altruist Biologics